Peptide Skin Barrier Intercepting Urushiol Allergens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic reactions primarily focus on symptom management rather than preventing the penetration or accumulation of allergens on the skin, which can lead to inflammatory responses and discomfort, particularly from urushiol allergens found in plants like poison ivy, oak, and sumac, affecting a significant portion of the population.
Innovation Solution
Development of peptide-based preparations containing 2 to 10 amino acids with reactive side chains that form a skin barrier to intercept and bind urushiol allergens, preventing their penetration and accumulation, thereby reducing the occurrence of allergic contact dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If the skin barrier is enhanced to prevent allergen penetration, then allergen accumulation is reduced, but the complexity of the protective mechanism increases
Solution Approach 1:
The patent introduces peptides as intermediary substances that bind to urushiol allergens through covalent interactions, preventing direct contact between allergens and skin proteins. These peptides act as mediators that intercept allergens before they can penetrate the skin barrier, thereby protecting against allergic contact dermatitis without requiring complex structural modifications to the skin itself
Solution Approach 2:
The invention extracts and isolates specific reactive amino acid sequences (peptides) from larger protein structures. By identifying and utilizing only the essential reactive portions of proteins that can bind urushiol, the patent creates simplified protective agents that maintain effectiveness while reducing complexity compared to using whole proteins or complex immune system components
2Reliability
If peptides with reactive side chains are used to bind urushiol, then allergen binding efficiency is improved, but the risk of peptide degradation increases
Solution Approach 1:
The patent applies local quality by concentrating reactive functionality in specific localized regions (reactive side chains of amino acids) within the peptide structure. Rather than requiring the entire peptide to be highly stable, the design allows reactive portions to be strategically positioned for optimal urushiol binding while accepting that these same portions may be more susceptible to degradation. The overall peptide structure provides sufficient stability to deliver this localized reactive function to the skin surface
Solution Approach 2:
The invention employs preliminary action by applying peptides topically to the skin surface before urushiol exposure occurs. This pre-positioning ensures that reactive peptides are already in place to immediately bind and neutralize allergens upon contact, preventing the need for complex in vivo activation processes. The peptides perform their protective function preemptively, reducing the need for highly stable long-term formulations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide-based skin barrier effectively reduces the amount and rate of allergen accumulation on the skin, preventing immune responses and alleviating allergic reactions, including those caused by urushiol, by forming covalent or other interactions with allergens, thus providing a novel antiallergic solution.
Implementation Method 1
forming covalent or other interactions with allergens
Implementation Method 2
bind urushiol allergens
Data Source
AI summary
Allergenic substances, allergens such as urushiols, are captured by peptides that consist of 2-10 amino acids, at least one amino acid having one or more reactive side chains. This barrier effect of the peptides, in particular in topically applicable preparations, leads to a novel anti-allergic form of therapy.